Back to glossary
Genetics

APOE ε4 allele (mechanism)

DEAPOE-ε4-Allel (Mechanismus)

Reviewed by

The APOE ε4 allele encodes apolipoprotein E isoform E4, which differs from the ε3 isoform at residue 112 (cysteine→arginine), altering lipoprotein binding preferences and reducing efficient clearance of triglyceride-rich remnants and LDL from circulation. In the brain, E4 impairs amyloid-β clearance via the blood-brain barrier and through astrocytic and microglial processing, promotes tau pathology, and potentiates neuroinflammation via microglial activation — effects partly independent of amyloid. The allele confers dose-dependent Alzheimer's disease risk: one ε4 copy increases risk approximately 3–4-fold, two copies approximately 8–12-fold in European populations, with risk magnitudes varying across ancestries. Despite its disease associations, the ε4 allele has been maintained at ~14% global allele frequency, likely reflecting ancient trade-offs involving immune function, fertility, and early cognitive performance.

Sources

  1. Fortea J, Pegueroles J, Alcolea D, et al.. (2024). Alzheimer's disease in Down syndrome: a genetic form of dementia. *Nature Medicine*doi:10.1038/s41591-024-02931-w
  2. Huang Y, Mahley RW. (2014). ApoE and Alzheimer's disease: advances in genetics, pathophysiology, and therapeutic approaches. *Neurobiology of Disease*doi:10.1016/j.nbd.2014.01.018